Literature DB >> 35707149

Novel Bicyclic Dione Compounds as KRAS Inhibitors for Treating Cancer.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35707149      PMCID： PMC9190276          DOI： 10.1021/acsmedchemlett.2c00221

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.

Authors:  M Reck; D P Carbone; M Garassino; F Barlesi
Journal:  Ann Oncol       Date:  2021-06-02       Impact factor: 32.976

Review 2.  Resistance looms for KRAS G12C inhibitors and rational tackling strategies.

Authors:  Junmin Zhang; Juanhong Zhang; Qing Liu; Xing-Xing Fan; Elaine Lai-Han Leung; Xiao-Jun Yao; Liang Liu
Journal:  Pharmacol Ther       Date:  2021-12-03       Impact factor: 12.310

Review 3.  Reflections on drug resistance to KRASG12C inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment.

Authors:  ZhaoYong Han; Ding Zhou; JiaMan Wang; Bruce Jiang; XiYu Liu
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2022-01-13       Impact factor: 11.414

Review 4.  Targeting KRAS G12C mutation in lung adenocarcinoma.

Authors:  Anjali Rohatgi; Ramaswamy Govindan
Journal:  Lung Cancer       Date:  2021-12-31       Impact factor: 5.705

Review 5.  KRAS mutation in pancreatic cancer.

Authors:  Ji Luo
Journal:  Semin Oncol       Date:  2021-02-23       Impact factor: 4.929

Review 6.  Targeting KRAS mutant lung cancer: light at the end of the tunnel.

Authors:  Matthias Drosten; Mariano Barbacid
Journal:  Mol Oncol       Date:  2022-01-18       Impact factor: 6.603
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.